ATTIVITA 'IN VITRO' DEL FLUCONAZOLE VS AMPFOTERICINA B NEI CONFRONTI DI CEPPI DI CRYPTOCOCCUS NEOFORMANS

Translated title of the contribution: Fluconazole vs amphotericin B: 'In vitro' activity against Cryptococcus neoformans

Research output: Contribution to journalArticlepeer-review

Abstract

In this study the authors evaluated the 'in vitro' susceptibility of yeasts isolated to an antimycotic drug, fluconazole, in order to evaluate if its minimal inhibitory concentrations (MIC) was comparable to those of amphotericin B, by the means of the tube dilution method. A sample of 27 strains of Cryptococcus neoformans isolated from immunocompromised host was tested. The results show that fluconazole has a MIC90 value on C. neoformans (MIC90: 25 μg/ml) higher than amphotericin B (MIC90: 6.25 μg/ml). This suggests that fluconazole does not represent an alternative to amphotericin B for the treatment of the acute phase of cryptococcal infection. However, fluconazole proved to be more useful in the management of discharged patients, because it allowed their home treatment and the prevention of the relapses.

Translated title of the contributionFluconazole vs amphotericin B: 'In vitro' activity against Cryptococcus neoformans
Original languageItalian
Pages (from-to)1089-1092
Number of pages4
JournalGiornale di Malattie Infettive e Parassitarie
Volume45
Issue number10-11
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Parasitology

Fingerprint Dive into the research topics of 'Fluconazole vs amphotericin B: 'In vitro' activity against Cryptococcus neoformans'. Together they form a unique fingerprint.

Cite this